Korro to Present at the 2026 Jefferies Global Healthcare Conference in London

Korro Bio (Nasdaq: KRRO) will present at the Jefferies Global Healthcare Conference in London on November 19, 2026.

Rhea-AI Summary

Korro Bio (Nasdaq: KRRO) will present at the Jefferies Global Healthcare Conference in London on November 19, 2026. Chief Executive Officer and President Ram Aiyar will speak at 8:00 AM GMT (3:00 AM ET). A live webcast will be available through the Events & Presentations page of Korro’s investor website, with a replay available for 90 days following the presentation.

Key Terms

rna-editing oligonucleotides, adenosine deaminases acting on RNA

2 terms

rna-editing oligonucleotides technical

"RNA-editing oligonucleotides (REOs) that modify the targeted native mRNA transcript"

Short, synthetic strands of nucleic acids designed to bind a specific cellular messenger RNA by base pairing and to direct or enable an enzymatic change to that RNA sequence or its processing. They work by creating a defined RNA duplex or recruiting an editing enzyme (commonly endogenous ADAR enzymes that convert adenosine to inosine, read as guanosine) or by otherwise altering splicing or chemical groups; the result changes the RNA transcript’s sequence or behavior without changing the underlying genomic DNA. Edits are transient and act at the RNA level, so their effects are reversible and require continued presence or expression of the oligonucleotide and any necessary editing machinery.

adenosine deaminases acting on RNA medical

"ADAR proteins (Adenosine Deaminases Acting on RNA)"

Adenosine deaminases acting on RNA (ADARs) are a family of enzymes that bind double-stranded regions of cellular RNA and chemically convert adenosine bases into inosine. Because cellular machinery reads inosine like guanosine, this A-to-I editing can change codons, alter splicing signals, modify RNA structure, or reduce recognition of RNA by innate immune sensors. ADAR activity is sequence- and structure-dependent and affects the function or fate of the edited RNAs rather than changing the underlying DNA.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA^®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the 2026 Jefferies Global Healthcare Conference in London being held on November 16-19, 2026.  Dr. Aiyar’s presentation will take place on Thursday, November 19^th at 8:00 AM GMT (3:00 AM ET).  

A live webcast of the presentation can be accessed on the “Events & Presentations” page in the investor section of Korro’s website at www.korrobio.com. Following the presentation a replay of the event will be available for 90 days.

About Korro

Korro is a clinical-stage biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA^®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases. OPERA provides precise, tissue-directed delivery of RNA-editing oligonucleotides (REOs) that modify the targeted native mRNA transcript to repair or form a de-novo protein with enhanced functionality. The platform combines a suite of capabilities consisting of sophisticated knowledge of transcription biology through ADAR proteins (Adenosine Deaminases Acting on RNA), machine learning optimization of REOs, linker chemistry expertise, along with use of a highly targeted tissue-specific delivery methodology.  As such, the OPERA platform has enabled Korro to generate and advance a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process, providing precise yet transient single base edits to produce therapeutic proteins with augmented activity versus its endogenous counterpart. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an REO-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary OPERA platform with precedented delivery modalities, including N-acetylgalactosamine (GalNAc) conjugated for delivery for subcutaneous administration, manufacturing know-how, and established regulatory pathways of approved oligonucleotide medicines. Korro is based in Cambridge, Massachusetts. For more information, visit korrobio.com.

Korro intends to use its Investor Relations website, LinkedIn, and X (Twitter) as means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor Korro’s Investor Relations website and follow @KorroBio on LinkedIn, and X (Twitter), in addition to following Korro’s press releases, SEC filings, public conference calls, presentations, and webcasts.

Korro Bio Contact Information

Investor & Media Contact
Malini Chatterjee, Ph.D
Blueprint Life Science Group
mchatterjee@bplifescience.com or ir@korrobio.com
917.330.4269